{"componentChunkName":"component---src-templates-chapter-level-1-chapter-level-1-tsx","path":"/topics/fungal-nail-infection/references/","result":{"pageContext":{"chapter":{"id":"74af204e-7571-5d05-963f-0c0614335fbf","slug":"references","fullItemName":"References","depth":1,"htmlHeader":"<!-- begin field c2d7293e-83a9-4c07-a9e7-b79a3c26bf62 --><h1>References</h1><!-- end field c2d7293e-83a9-4c07-a9e7-b79a3c26bf62 -->","summary":null,"htmlStringContent":"<!-- begin item 33c2bf8e-f571-4fb1-8b22-a367178fcfb2 --><!-- begin field b1c17805-f672-4566-96d2-389ec9c90256 --><ul class=\"bibliography\"><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    ABPI                </span> (<span property=\"dcterms:issued\">2013</span>) <em><span property=\"dc:title\">SPC for Amorolfine 5% w/v Medicated Nail Lacquer (Arrow)</span></em>. <span property=\"dc:publisher\">Datapharm Communications Ltd</span>. <span rel=\"bibo:Website\"><a href=\"http://www.medicines.org.uk/\" target=\"_blank\" class=\"website\" data-hyperlink-id=\"4043a9cf-25c9-4f76-af8e-ac03006e55d6\">http://www.medicines.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"http://www.medicines.org.uk/emc/medicine/27934/SPC/Amorolfine+5++w+v+Medicated+Nail+Lacquer+%28Arrow%29\" target=\"_blank\" class=\"fulltextlink\" data-hyperlink-id=\"62b5a060-258e-47ab-a525-ac03006e560a\">Free Full-text</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    ABPI                </span> (<span property=\"dcterms:issued\">2016</span>) <em><span property=\"dc:title\">SPC for&#160;Itraconazole 100 mg Capsules</span></em>. <span property=\"bibo:Collection\">Electronic Medicines Compendium</span>. <span property=\"dc:publisher\">Datapharm Communications Ltd.</span> <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc\" target=\"_blank\" class=\"website\" data-hyperlink-id=\"73ad2c8b-4f86-42db-b5e3-ac07017a04cd\">https://www.medicines.org.uk/emc</a></span> [<span rel=\"bibo:uri\"><a href=\"http://www.medicines.org.uk/emc/medicine/32181#PRODUCTINFO\" target=\"_blank\" class=\"fulltextlink\" data-hyperlink-id=\"0a58d5e7-9872-4aab-8cdb-ac07017a04de\">Free Full-text</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    ABPI                </span> (<span property=\"dcterms:issued\">2017</span>) <em><span property=\"dc:title\">SPC for&#160;Terbinafine 250mg tablets</span></em>. <span property=\"bibo:Collection\">Electronic Medicines Compendium</span>. <span property=\"dc:publisher\">Datapharm Communications Ltd.</span> <span rel=\"bibo:Website\"><a href=\"https://www.medicines.org.uk/emc\" target=\"_blank\" class=\"website\" data-hyperlink-id=\"20b84dad-e455-4167-82e6-ac0701852013\">https://www.medicines.org.uk/emc</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.medicines.org.uk/emc/product/8452\" target=\"_blank\" class=\"fulltextlink\" data-hyperlink-id=\"9019a759-8250-4dd7-a948-ac070185202a\">Free Full-text</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Al-Mutairi, N., Eassa, B.I. and Al-Rqobah, D.A.                </span> (<span property=\"dcterms:issued\">2010</span>) <span property=\"dc:title\">Clinical and mycologic characteristics of onychomycosis in diabetic patients</span>. <em>Acta Dermatovenerol Croat</em> <strong><span rel=\"bibo:volume\">18</span></strong>(<span rel=\"bibo:issue\">2</span>),  84-91. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20624357\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"5325b582-01a8-44b4-929f-ac070188f9d6\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Ameen, M., Lear, J.T., Madan, V.                        <em>et al.</em>                </span> (<span property=\"dcterms:issued\">2014</span>) <span property=\"dc:title\">British Association of Dermatologists&#39; guidelines for the management of onychomycosis 2014</span>. <em>British Journal of Dermatology</em> <strong><span rel=\"bibo:volume\">171</span></strong>(<span rel=\"bibo:issue\">5</span>),  937-958. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25409999\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"edc6cd1b-10c9-45de-aa2f-ac070188f2f7\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    BNF                </span> (<span property=\"dcterms:issued\">2018</span>) <em><span property=\"dc:title\">British National Formulary</span></em>. 75th edn. London:  <span property=\"dc:publisher\">British Medical Association and Royal Pharmaceutical Society</span>.            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    de Sa, D., Lamas, A. and Tosti, A.                </span> (<span property=\"dcterms:issued\">2014</span>) <span property=\"dc:title\">Oral therapy for onychomycosis: an evidence-based review</span>. <em>Am J Clin Dermatol</em> <strong><span rel=\"bibo:volume\">15</span></strong>(<span rel=\"bibo:issue\">1</span>),  17-36. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24352873\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"274dd802-2705-4b0b-b636-ac070188f3cc\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Eisman, S. Sinclair, R.                </span> (<span property=\"dcterms:issued\">2014</span>) <span property=\"dc:title\">Fungal nail infection: diagnosis and management</span>. <em>British Medical Journal</em> <strong><span rel=\"bibo:volume\">348</span></strong>,  1-11. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24661991\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"711ca3f0-e331-4e4b-a08a-ac070188f787\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Feng, X., Xincai, X. and Ran, Y.                </span> (<span property=\"dcterms:issued\">2017</span>) <span property=\"dc:title\">Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: a meta-analysis and systematic review</span>. <em>Dermatologic Therapy</em> <strong><span rel=\"bibo:volume\">30</span></strong>(<span rel=\"bibo:issue\">3</span>),  1-6. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28097731\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"98025cef-bc67-4b86-894f-ac070188f83b\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Gupta, A.K., Lynde, C.W., Jain, H.C.,                        <em>et al.</em>                </span> (<span property=\"dcterms:issued\">1997</span>) <span property=\"dc:title\">A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study</span>. <em>British Journal of Dermatology</em> <strong><span rel=\"bibo:volume\">136</span></strong>(<span rel=\"bibo:issue\">5</span>),  786-789. [<span rel=\"bibo:abstract\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/9205520\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"82775a4d-b85e-45aa-990e-ac0901853e2e\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Gupta, A.K., Daigle, D. and Foley, K.A.                </span> (<span property=\"dcterms:issued\">2014</span>) <span property=\"dc:title\">Topical therapy for toenail onychomycosis: an evidence-based review</span>. <em>Am J Clin Dermatol</em> <strong><span rel=\"bibo:volume\">15</span></strong>(<span rel=\"bibo:issue\">6</span>),  489-502. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25257931\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"432b1279-c53d-496e-a119-ac070188f47f\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Gupta, A.K., Daigle, D. and Foley, K.A.                </span> (<span property=\"dcterms:issued\">2015</span>) <span property=\"dc:title\">Network meta-analysis of onychomycosis treatments</span>. <em>Skin Appendage Disord</em> <strong><span rel=\"bibo:volume\">1</span></strong>(<span rel=\"bibo:issue\">2</span>),  74-81. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27170937\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"a397bc8e-6549-4b81-9d5a-ac070188f5ee\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Kreijkamp-Kaspers, S., Hawke, K., Guo, L.                        <em>et al.</em>                </span> (<span property=\"dcterms:issued\">2017</span>) <em><span property=\"dc:title\">Oral antifungal medication for toenail onychomycosis (Cochrane Review)</span></em>. <span property=\"bibo:issue\">Issue 7</span>. <span property=\"dc:publisher\">John Wiley &amp; Sons, Ltd.</span> <span rel=\"bibo:Website\"><a href=\"http://www.cochranelibrary.com/\" target=\"_blank\" class=\"website\" data-hyperlink-id=\"0614fd15-2677-4a05-a879-ac0200c078ce\">http://www.cochranelibrary.com</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010031.pub2/full\" target=\"_blank\" class=\"fulltextlink\" data-hyperlink-id=\"23a6ed6b-f422-4532-8dc2-ac0200c079a9\">Free Full-text</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Lynde, C.                </span> (<span property=\"dcterms:issued\">2001</span>) <span property=\"dc:title\">Nail disorders that mimic onychomycosis: what to consider</span>. <em>Cutis</em> <strong><span rel=\"bibo:volume\">68</span></strong>(<span rel=\"bibo:issue\">2 Suppl</span>),  8-12. [<span rel=\"bibo:abstract\"><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/11665727\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"bfe5a084-e2ac-4217-aad1-ac090169722a\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    NICE                </span> (<span property=\"dcterms:issued\">2017</span>) <em><span property=\"dc:title\">Suspected cancer: recognition and referral</span></em>. <span property=\"dc:publisher\">National Institute for Health and Care Excellence</span>. <span rel=\"bibo:Website\"><a href=\"https://www.nice.org.uk/\" target=\"_blank\" class=\"website\" data-hyperlink-id=\"cb00107a-4a89-4065-9acb-ab59010a22c8\">https://www.nice.org.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.nice.org.uk/guidance/ng12\" target=\"_blank\" class=\"fulltextlink\" data-hyperlink-id=\"1ad44198-5bab-40f0-88bd-ab59010a22e7\">Free Full-text</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Public Health England                </span> (<span property=\"dcterms:issued\">2017</span>) <em><span property=\"dc:title\">Fungal skin and nail infections: Diagnosis and laboratory investigation</span></em>. <span property=\"dc:publisher\">Public Health England</span>. <span rel=\"bibo:Website\"><a href=\"http://www.gov.uk/\" target=\"_blank\" class=\"website\" data-hyperlink-id=\"96a7c345-f5eb-4252-b6a0-ac030089ea59\">http://www.gov.uk</a></span> [<span rel=\"bibo:uri\"><a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/619770/Fungal_skin_and_nail_infections_guidance.pdf\" target=\"_blank\" class=\"fulltextlink\" data-hyperlink-id=\"51d5cabc-8695-48df-9c6a-ac030089ea77\">Free Full-text</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Philpot, C.M. and Shuttleworth, D.                </span> (<span property=\"dcterms:issued\">1989</span>) <span property=\"dc:title\">Dermatophyte onychomycosis in children</span>. <em>Clin Exp Dermatol</em> <strong><span rel=\"bibo:volume\">14</span></strong>(<span rel=\"bibo:issue\">3</span>),  203-205. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/2531638\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"8f209158-465c-4583-a91a-ac070188fb36\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:editorList\">                    Preston, C.L.                </span> (Eds.) (<span property=\"dcterms:issued\">2016</span>) <em><span property=\"dc:title\">Stockley&#39;s drug interactions 2015: pocket companion</span></em>. London:  <span property=\"dc:publisher\">Pharmaceutical Press</span>.            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Scher, R.K. and Baran, R.                </span> (<span property=\"dcterms:issued\">2003</span>) <span property=\"dc:title\">Onychomycosis in clinical practice: factors contributing to recurrence</span>. <em>British Journal of Dermatology</em> <strong><span rel=\"bibo:volume\">149</span></strong>(<span rel=\"bibo:issue\">S65</span>),  5-9. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/14510969\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"3f547250-8e2d-4d0a-ad2e-ac070188f53c\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Sigurgeirsson, B. and Baran, R.                </span> (<span property=\"dcterms:issued\">2014</span>) <span property=\"dc:title\">The prevalence of onychomycosis in the global population - a literature study</span>. <em>J Eur Acad Dermatol Venereol</em> <strong><span rel=\"bibo:volume\">28</span></strong>(<span rel=\"bibo:issue\">11</span>),  1480-1491. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24283696\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"b8527570-f774-4cf6-b577-ac070188fa86\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Tosti, A. and Elewski, B.E.                </span> (<span property=\"dcterms:issued\">2016</span>) <span property=\"dc:title\">Onychomycosis: practical approaches to minimize relapse and recurrence</span>. <em>Skin Appendage Disord</em> <strong><span rel=\"bibo:volume\">2</span></strong>(<span rel=\"bibo:issue\">1</span>),  83-87. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/27843933\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"33ad9c47-8a4c-4e2f-b80f-ac070188f6d5\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Westerberg, D.P. and Voyack, M.J.                </span> (<span property=\"dcterms:issued\">2013</span>) <span property=\"dc:title\">Onychomycosis: current trends in diagnosis and treatment</span>. <em>American Family Physician</em> <strong><span rel=\"bibo:volume\">88</span></strong>(<span rel=\"bibo:issue\">11</span>),  762-770. [<span rel=\"bibo:abstract\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24364524\" target=\"_blank\" class=\"abstract\" data-hyperlink-id=\"792fa681-55f2-4da6-bb3b-ac070188f910\">Abstract</a></span>]            </span></li><li><span property=\"bibo:Article\">                <span property=\"bibo:authorList\">                    Williams, H.C.                </span> (<span property=\"dcterms:issued\">1993</span>) <span property=\"dc:title\">The epidemiology of onychomycosis in Britain</span>. <em>British Journal of Dermatology</em> <strong><span rel=\"bibo:volume\">129</span></strong>(<span rel=\"bibo:issue\">2</span>),  101-109.            </span></li></ul><!-- end field b1c17805-f672-4566-96d2-389ec9c90256 --><!-- end item 33c2bf8e-f571-4fb1-8b22-a367178fcfb2 -->","topic":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151","topicId":"d2c6135f-fef1-4a56-80dc-161c93380c7d","topicName":"Fungal nail infection","slug":"fungal-nail-infection","lastRevised":"Last revised in March 2018","chapters":[{"id":"bc563964-f1b0-559d-9f21-380162710ddf","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dd347390-fb63-5e80-9fab-bd3cc4704341","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0cdd100c-c9d0-5685-980c-52f246d1100e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"886d32db-68df-5055-b459-55404c1f011e","slug":"changes","fullItemName":"Changes"},{"id":"c1cacd2b-dba0-5341-a274-66fd882b2036","slug":"update","fullItemName":"Update"}]},{"id":"9f0a65a3-9309-5a00-a9fa-bda2fb7a49c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1121797b-5555-5e24-a9ae-aabc657725dd","slug":"goals","fullItemName":"Goals"},{"id":"aa660497-e222-5e9d-b282-3069500c380f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49df22af-d1aa-56cd-b2dc-30e6ecc84ca8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a79a5fd4-4f6a-5d37-8714-e4bd3bea76b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6db25a8b-db82-5b72-bade-fa216c349fd8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2515b15e-47ac-5e93-acaf-588daa2e06f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d257da5b-218f-50fc-96b1-55ec4b44f5cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ccd879d-9979-5f0b-b655-8da37ca04149","slug":"definition","fullItemName":"Definition"},{"id":"20d20421-b2ba-513f-87b5-3fad4f731aa5","slug":"causes","fullItemName":"Causes"},{"id":"3142330a-0287-5835-8a69-857972828fb2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"29b083db-9488-5407-92df-43f4952d8df3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d7dd4e0b-6a97-5db7-bfa3-aa690c7974af","slug":"complications","fullItemName":"Complications"},{"id":"3a29be3f-ea9f-56a3-b8d7-78341665856e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4346dd42-e5eb-550e-a004-7c8e7103a196","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6a7486c-a6d8-5d8b-918c-8610bf76e212","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"eec0a81e-c0c0-5f9d-951e-f19c41cfafaf","slug":"assessment","fullItemName":"Assessment"},{"id":"d84aa70d-b236-5783-9eeb-e1181b1311f8","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","fullItemName":"Management","slug":"management","subChapters":[{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine"},{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"0b102b3a-ebce-5c6e-9670-3610defc871d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bc0bd4bc-1b10-52dc-b942-cd4682774d01","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dc202e28-37b1-5789-a14a-b5a0850d8cf8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49993e8c-ae7a-5891-bf43-21a6406ce1b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b6aa45b7-d833-599f-8bcc-4d08c6c264bb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2805cbb7-09b5-5875-a0c1-c501223c6ab3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"595745a2-d654-5e3b-850e-eac6532bd5db","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74af204e-7571-5d05-963f-0c0614335fbf","fullItemName":"References","slug":"references","subChapters":[]}]},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}